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KEY POINTS
 All invasive procedures involve contact by amedical device or surgical instrument with pa-
tients’ sterile tissue or mucous membrane.
 The level of disinfection or sterilization depends on the intended use of the object: critical
(items that contact sterile tissue, such as surgical instrument), semicritical (items that con-
tact mucous membranes, such as endoscopes), and noncritical (items that contact only
intact skin, such as stethoscopes) require sterilization, high-level disinfection, or low-
level disinfection, respectively.
 Cleaning must precede high-level disinfection and sterilization.
 Failure to properly disinfect devices used in health care (eg, endoscopes) has led to many
outbreaks.
 Health care providers should be familiar with current issues, such as the role of the envi-
ronment in disease transmission, reprocessing semicritical items (eg, endoscopes), and
new technologies (eg, hydrogen peroxide mist).INTRODUCTION
In the United States in 2010 there were approximately 51.4 million inpatient surgical
procedures and an even larger number of invasive medical procedures.1 In 2009, there
were more than 6.9 million gastrointestinal (GI) upper, 11.5 million GI lower, and
228,000 biliary endoscopies performed.2 Each of these procedures involves contact
by a medical device or surgical instrument with patients’ sterile tissue or mucous
membranes. A major risk of all such procedures is the introduction of pathogenicPotential Conflicts of Interest: Dr W.A. Rutala is a consultant for Clorox and has received hon-
oraria from 3M. Dr D.J. Weber is a consultant for Clorox and Germitec.
a Hospital Epidemiology, University of North Carolina Health Care System, Chapel Hill, NC
27514, USA; b Division of Infectious Diseases, University of North Carolina School of Medicine,
Chapel Hill, NC 27599-7030, USA
* Corresponding author. Hospital Epidemiology, UNC Hospitals, Room 1001, West Wing, Mann-
ing Drive, Chapel Hill, NC 27599-7030.
E-mail address: brutala@unch.unc.edu
Infect Dis Clin N Am 30 (2016) 609–637
http://dx.doi.org/10.1016/j.idc.2016.04.002
microbes, which can lead to infection. Failure to properly disinfect or sterilize equip-
ment may lead to transmission via contaminated medical and surgical devices (eg, 
carbapenem-resistant Enterobacteriaceae [CRE]).3,4
Achieving disinfection and sterilization through the use of disinfectants and steriliza-
tion practices is essential for ensuring that medical and surgical instruments do not 
transmit infectious pathogens to patients. Because it is not necessary to sterilize all 
patient-care items, health care policies must identify whether cleaning, disinfection, 
or sterilization is indicated based primarily on each item’s intended use, manufacturers 
recommendations, and guidelines.
Multiple studies in many countries have documented lack of compliance with estab-
lished guidelines for disinfection and sterilization.5 Failure to comply with scientifically 
based guidelines has led to numerous outbreaks and patient exposures.6–8 Because 
of noncompliance with recommended reprocessing procedures, the Centers for 
Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) 
issued a health advisory alerting health care providers and facilities about the public 
health need to properly maintain, clean, and disinfect and sterilize reusable medical 
devices in September 2015.9 In this article, which is an updated and modified version 
of earlier articles,10–14 a pragmatic approach to the judicious selection and proper use 
of disinfection and sterilization processes is presented, based on well-designed 
studies assessing the efficacy (via laboratory investigations) and effectiveness (via 
clinical studies) of disinfection and sterilization procedures.A RATIONAL APPROACH TO DISINFECTION AND STERILIZATION
Almost 50 years ago, Earle H. Spaulding15 devised a rational approach to disinfection 
and sterilization of patient-care items or equipment. This classification scheme is so 
clear and logical that it has been retained, refined, and successfully used by infection 
control professionals and others when planning methods for disinfection or steriliza-
tion.10–14 Spaulding thought that the nature of disinfection could be understood 
more readily if instruments and items for patient care were divided into 3 categories 
based on the degree of risk of infection involved in the use of the items. The 3 cate-
gories he described were critical, semicritical, and noncritical. This terminology is 
used by the CDC’s “Guidelines for Environmental Infection Control in Healthcare Fa-
cilities”16 and the CDC’s “Guideline for Disinfection and Sterilization in Healthcare Fa-
cilities.”13 These categories and the methods to achieve sterilization, high-level 
disinfection, and low-level disinfection are summarized in Table 1. Although the 
scheme remains valid, there are some examples of disinfection studies with prions, vi-
ruses, mycobacteria, and protozoa that challenge the current definitions and expec-
tations of high-level disinfection (HLD) and low-level disinfection.22
In May 2015, the FDA convened a panel to discuss recent reports and epidemio-
logic investigations of the transmission of infections associated with the use of duode-
noscopes in endoscopic retrograde cholangiopancreatography (ERCP) procedures.23 
After presentations from industry, professional societies, and invited speakers, the 
panel made several recommendations to include reclassifying duodenoscopes based 
on the Spaulding classification from semicritical to critical to support the shift from 
HLD to sterilization.24 This change could be accomplished by shifting from HLD for 
duodenoscopes to sterilization and modifying the Spaulding definition of critical items 
from “objects which enter sterile tissue or the vascular system or through which blood 
flows should be sterile” to “objects which directly or secondarily (ie, via a mucous 
membrane such as duodenoscope) enter normally sterile tissue of the vascular system 
of through which blood flows should be sterile.”24,25 Implementation of this
Table 1
Methods for disinfection and sterilization of patient-care items and environmental surfaces
Process Level of Microbial Inactivation Method Examples (with Processing Times) Health Care Application (Examples)
Sterilizationa Destroys all microorganisms,
including bacterial spores





Low temperature Ethylene oxide gas (w15 h), HP gas
plasma (28–52 min), HP and ozone
(46 min), HP vapor (55 min)
Heat-sensitive critical and semicritical
patient-care items
Liquid immersion Chemical sterilantsb: >2% glut
(w10 h); 1.12% glut with 1.93%
phenol (12 h); 7.35% HP with 0.23%
PA (3 h); 8.3% HP with 7.0% PA
(5 h); 7.5% HP (6 h); 1.0% HP with
0.08% PA (8 h);0.2% PA (12 min at
50C–56C)
Heat-sensitive critical and semicritical
patient-care items that can be
immersed
HLD Destroys all microorganisms
except some bacterial spores
Heat automated Pasteurization (65C–77C, 30 min) Heat-sensitive semicritical items (eg,
respiratory therapy equipment)
Liquid immersion Chemical sterilants/HLDsb: >2% glut
(20–90 min at 20C–25C); >2% glut
(5 min at 35.0C–37.8C); 0.55%
OPA (12 min at 20C); 1.12% glut
with 1.93% phenol (20 min at 25C);
7.35% HP with 0.23% PA (15 min at
20C); 7.5% HP (30 min at 20C);
1.0% HP with 0.08% PA (25 min);
400–450 ppm chlorine (10 min at
20C); 2.0%HP (8min at 20C); 3.4%
glut with 26% isopropanol (10 min
at 20C)
Heat-sensitive semicritical items (eg,
GI endoscopes, bronchoscopes,
endocavitary probes)
(continued on next page)
Table 1
(continued )
Process Level of Microbial Inactivation Method Examples (with Processing Times) Health Care Application (Examples)
Low-level
disinfection
Destroys vegetative bacteria and
some fungi and viruses but not
mycobacteria or spores
Liquid contact EPA-registered hospital disinfectant
with no tuberculocidal claim (eg,
chlorine-based products, phenolics,
improved HP, HP plus PA,
quaternary ammonium compounds,
exposure times at least 1 min) or
70%–90% alcohol
Noncritical patient care item (blood
pressure cuff) or surface (bedside
table) with no visible blood
Abbreviations: EPA, Environmental Protection Agency; glut, glutaraldehyde; HLD, high-level disinfection; HP, hydrogen peroxide; OPA, ortho-phthalaldehyde; PA,
peracetic acid; ppm, parts per million.
a Prions (such as Creutzfeldt-Jakob disease) exhibit an unusual resistance to conventional chemical and physical decontamination methods and are not readily
inactivated by conventional sterilization procedures.17
b Consult the FDA-cleared package insert for information about the cleared contact time and temperature, and see reference18 for discussion why greater than
2% glutaraldehyde products are used at a reduced exposure time (2% glutaraldehyde at 20 minutes, 20C). Increasing the temperature using an automated endo-
scope reprocesser (AER) will reduce the contact time (eg, ortho-phthalaldehyde 12 minutes at 20C but 5 minutes at 25C in AER). Exposure temperatures for some
of the aforementioned high-level disinfectants varies from 20C to 25C; check FDA-cleared temperature conditions.19 Tubing must be completely filled for high-
level disinfection and liquid chemical sterilization. Material compatibility should be investigated when appropriate (eg, hydrogen peroxide [HP] and HP with per-
acetic acid will cause functional damage to endoscopes). Intermediate-level disinfectants destroy vegetative bacteria, mycobacteria, most viruses, and most fungi
but not spores and may include chlorine-based products, phenolics, and improved HP. Intermediate-level disinfectants are not included in Table 1 as there as there
is no device or surface for which intermediate-level disinfection is specifically recommended over low-level disinfection.
Adapted from Refs.11–13,20,21
recommendations requires sterilization technology that achieves a sterility assurance
level of 106 of complex medical instruments, such as duodenoscopes. Ideally, this
shift would eventually involve not only endoscopes that secondarily enter normally
sterile tissue (eg, duodenoscopes, bronchoscopes) but also other semicritical devices
(eg, GI endoscopes).24,25
Critical Items
Critical items are so called because of the high risk of infection if such an item is
contaminated with any microorganism, including bacterial spores. Thus, it is critical
that objects that enter sterile tissue or the vascular system be sterile because any mi-
crobial contamination could result in disease transmission. This category includes sur-
gical instruments, cardiac and urinary catheters, and implants used in sterile body
cavities. The items in this category should be purchased as sterile or be sterilized
by steam sterilization if possible. If heat sensitive, the object may be treated with
ethylene oxide (ETO), hydrogen peroxide (HP) gas plasma, vaporized HP, HP vapor
(HPV) plus ozone, or by liquid chemical sterilants if other methods are unsuitable.
Table 1 and Tables 2 and 3 list sterilization processes and liquid chemical sterilants
and the advantages and disadvantages of each. With the exception of 0.2% peracetic
acid (12 minutes at 50C–56C), the indicated exposure times for liquid chemical ster-
ilants range from 3 to 12 hours.19 Liquid chemical sterilants can be relied on to pro-
duce sterility only if cleaning, which eliminates organic and inorganic material,
precedes treatment and if proper guidelines as to concentration, contact time, tem-
perature, and pH are met. Another limitation to sterilization of devices with liquid
chemical sterilants is that the devices cannot be wrapped during processing in a liquid
chemical sterilant; thus, it is impossible to maintain sterility following processing and
during storage. Furthermore, devices may require rinsing following exposure to the
liquid chemical sterilant with water that, in general, is not sterile. Therefore, because
of the inherent limitations of using liquid chemical sterilants in a nonautomated (or
automated) reprocessor, their use should be restricted to reprocessing critical devices
that are heat sensitive and incompatible with other sterilization methods.
In contrast to semicritical items that have been associated with greater than 100
outbreaks of infection,6 critical items have rarely,26 if ever, been associated with dis-
ease transmission. For example, any deviation from proper reprocessing (such as
crevices associated with the elevator channel) of an endoscope could lead to failure
to eliminate contamination with a possibility of subsequent patient-to-patient trans-
mission due to a low or nonexistent margin of safety. This low (or nonexistent) margin
of safety associated with endoscope reprocessing compares with the 17-log10 margin
of safety associated with cleaning and sterilization of surgical instruments (ie, 12-log10
reduction via sterilization and at least a net 5-log10 reduction based on the microbial
load on surgical instruments [2-logs]27 and microbial reduction via a washer disinfec-
tor [7-logs]).18
Semicritical Items
Semicritical items are those that come in contact with mucous membranes or nonin-
tact skin. Respiratory therapy and anesthesia equipment, gastrointestinal endo-
scopes, bronchoscopes, laryngoscopes, endocavitary probes, prostate biopsy
probes,28 cystoscopes,29 hysteroscopes, infrared coagulation devices,30 and dia-
phragm fitting rings are included in this category. These medical devices should be
free of all microorganisms (ie, mycobacteria, fungi, viruses, bacteria), although small
numbers of bacterial spores may be present. Intact mucous membranes, such as
those of the lungs or the gastrointestinal tract, are generally resistant to infection by
Table 2





 No activation required
 Odor or irritation not significant
 Material compatibility concerns (lead, brass, copper, zinc) both
cosmetic and functional
 Limited clinical experience
 Potential for eye and skin damage
Glutaraldehyde  Numerous use studies published
 Relatively inexpensive
 Excellent material compatibility
 Respiratory irritation from glutaraldehyde vapor
 Pungent and irritating odor
 Relatively slow mycobactericidal activity (unless other disinfectants
added such as phenolic, alcohol)
 Coagulates blood and fixes tissue to surfaces
 Allergic contact dermatitis
HP  No activation required
 May enhance removal of organic matter and organisms
 No disposal issues
 No odor or irritation issues
 Does not coagulate blood or fix tissues to surfaces
 Inactivates Cryptosporidium
 Use studies published
 Material compatibility concerns (brass, zinc, copper, and nickel/sil-
ver plating) both cosmetic and functional
 Serious eye damage with contact
OPA  Fast-acting high-level disinfectant
 No activation required
 Odor not significant
 Excellent materials compatibility claimed
 Does not coagulate blood or fix tissues to surfaces claimed
 Stains protein gray (eg, skin, mucous membranes, clothing, and
environmental surfaces)
 Limited clinical experience
 More expensive than glutaraldehyde
 Eye irritation with contact
 Slow sporicidal activity
 Anaphylactic reactions to OPA in patients with bladder cancer with
repeated exposure to OPA through cystoscopy
Peracetic acid  Standardized cycle (eg, Liquid Chemical Sterilant Processing System
using Peracetic Acid, rinsed with extensively treated potable water)
 Low temperature (50C–55C) liquid immersion sterilization
 Environmental friendly byproducts (acetic acid, O2, H20)
 Fully automated
 Single-use system eliminates need for concentration testing
 May enhance removal of organic material and endotoxin
 No adverse health effects to operators under normal operating
conditions
 Compatible with many materials and instruments
 Does not coagulate blood or fix tissues to surfaces
 Sterilant flows through scope facilitating salt, protein, and microbe
removal
 Rapidly sporicidal
 Provides procedure standardization (constant dilution, perfusion of
channel, temperatures, exposure)
 Potential material incompatibility (eg, aluminum anodized coating
becomes dull)
 Used for immersible instruments only
 Biological indicator may not be suitable for routine monitoring
 One scope or a small number of instruments can be processed in a
cycle
 More expensive (endoscope repairs, operating costs, purchase
costs) than high-level disinfection
 Serious eye and skin damage (concentrated solution) with contact
 Point-of-use system, no sterile storage




 No activation required
 No odor
 Nonstaining
 No special venting requirements
 Manual or automated applications
 12-mo shelf-life, 14-d reuse
 8 min at 20C HLD claim
 Material compatibility concerns due to limited clinical experience
 Antimicrobial claims not independently verified
 Organic material resistance concerns due to limited data
Abbreviations: AER, automated endoscope reprocessor; OPA, ortho-phthalaldehyde.
a All products effective in presence of organic soil, relatively easy to use, and have a broad spectrum of antimicrobial activity (bacteria, fungi, viruses, bacterial
spores, and mycobacteria). The aforementioned characteristics are documented in the literature; contact the manufacturer of the instrument and sterilant for
additional information. All products listed are cleared by the FDA as chemical sterilants except ortho-phthalaldehyde, which is an FDA-cleared HLD.
Adapted from Refs.10–13,20
Table 3
Summary of advantages and disadvantages of commonly used sterilization technologies
Sterilization
Method Advantages Disadvantages
Steam  Nontoxic to patients, staff,
environment
 Cycle easy to control and monitor
 Rapidly microbicidal
 Least affected by organic/inor-
ganic soils among sterilization
processes listed
 Rapid cycle time
 Penetrates medical packaging,
device lumens
 It is deleterious for heat-sensitive
instruments.
 Microsurgical instruments are
damaged by repeated exposure.
 It may leave instruments wet,
causing them to rust.
 There is potential for burns.
HP gas plasma  Safe for the environment and
health care personnel
 Leaves no toxic residuals
 Cycle time 28 min, and no aera-
tion necessary
 Used for heat- and moisture-
sensitive items because process
temperature <50C
 Simple to operate, install (208-V
outlet), and monitor
 Compatible with most medical
devices
 Only requires electrical outlet
 Cellulose (paper), linens, and
liquids cannot be processed.
 Endoscope or medical device
restrictions are based on lumen
internal diameter and length (see
manufacturer’s
recommendations).
 It requires synthetic packaging
(polypropylene wraps, polyolefin
pouches) and a special container
tray.
 HP may be toxic at levels >1 ppm
TWA.
100% ETO  Penetrates packaging materials,
device lumens
 Potential for gas leak and ETO
exposure minimized by single-
dose cartridge and negative-
pressure chamber
 Simple to operate and monitor
 Compatible with most medical
materials
 It requires aeration time to
remove ETO residue.
 ETO is toxic, a carcinogen, and
flammable.
 ETO emission is regulated by
states, but catalytic cell removes
99.9% of ETO and converts it to
carbon dioxide and water.
 ETO cartridges should be stored in
flammable liquid storage cabinet.
 It has a lengthy cycle/aeration
time.
Vaporized HP  Safe for the environment and
health care personnel
 Leaves no toxic residue; no aera-
tion necessary
 Cycle time 55 min
 Used for heat- and moisture-
sensitive items (metal and
nonmetal devices)
 Medical device restrictions are
based on lumen internal diameter
and length; see manufacturer’s
recommendations (eg, stainless
steel lumen 1 mm diameter,
125 mm length).
 It is not used for liquid, linens,
powders, or any cellulose
materials.
 Requires synthetic packaging
(polypropylene).
 There are limited materials
compatibility data.
 There are limited clinical use and
comparative microbicidal efficacy
data.





HP and ozone  Safe for the environment and
health care personnel
 Uses dual sterilants, HP, and ozone
 Does not need aeration because
of no toxic byproducts
 Compatible with common
medical devices
 Cycle time 46 min
 FDA cleared for general instru-
ments, single-channel flexible
endoscopes, and rigid and
semirigid channeled devices
 Endoscope or medical device
restrictions are based on lumen
internal diameter and length (see
manufacturer’s
recommendations).
 There are limited clinical use (no
published data on material
compatibility/penetrability/
organic material resistance) and
limited microbicidal efficacy data.
 It requires synthetic packaging
(polypropylene wraps, polyolefin
pouches) and a special container
tray.
Abbreviations: ETO, ethylene oxide; HP, hydrogen peroxide; TWA, time-weighted average.
Adapted from Refs.10–13,20common bacterial spores but susceptible to other organisms, such as bacteria, myco-
bacteria, and viruses. Semicritical items minimally require HLD using chemical disin-
fectants. Glutaraldehyde, HP, ortho-phthalaldehyde (OPA), peracetic acid with HP,
and chlorine (via electrochemical activation) are cleared by the FDA19 and are depend-
able high-level disinfectants provided the factors influencing germicidal procedures
are met (see Tables 1 and 2). The exposure time for most high-level disinfectants
varies from 8 to 45 minutes at 20C to 25C.19
Because semicritical equipment has been associated with reprocessing errors that
result in patient lookback and patient notifications, it is essential that control measures
be instituted to prevent patient exposures.7 Before new equipment (especially semi-
critical equipment as the margin of safety is less than that for sterilization)25 is used
for patient care on more than one patient, reprocessing procedures for that equipment
should be developed. Staff should receive training on the safe use and reprocessing of
the equipment and be competency tested. At the University of North Carolina (UNC)
Hospitals, to ensure patient-safe instruments, all staff that reprocess semicritical in-
struments (eg, instruments which contact a mucous membrane such as vaginal
probes, endoscopes, prostate probes) are required to attend a 3-hour class on HLD
of semicritical instruments. The class includes the rationale for and importance of
high-level disinfection, discussion of high-level disinfectants and exposure times,
reprocessing steps, monitoring minimum effective concentration, personal protective
equipment, and the reprocessing environment (establish dirty-to-clean flow). Infection
control rounds or audits should be conducted annually in all clinical areas that repro-
cess critical and semicritical devices to ensure adherence to the reprocessing stan-
dards and policies. Results of infection control rounds should be provided to the
unit managers, and deficiencies in reprocessing should be corrected and the correc-
tive measures documented to infection control within 2 weeks (immediately correct
patient safety issues, such as exposure time to high-level disinfectant).
Noncritical Items
Noncritical items are those that come in contact with intact skin but not mucous mem-
branes. Intact skin acts as an effective barrier to most microorganisms; therefore, the
sterility of items coming in contact with intact skin is “not critical.” Examples of noncrit-
ical items are bedpans, blood pressure cuffs, crutches, bed rails, linens, bedside ta-
bles, patient furniture, and floors. In contrast to critical and some semicritical items, 
most noncritical reusable items may be decontaminated where they are used and 
do not need to be transported to a central processing area. There is virtually no docu-
mented risk of transmitting infectious agents to patients via noncritical items31 when 
they are used as noncritical items and do not contact nonintact skin and/or mucous 
membranes. However, these items (eg, bedside tables, bed rails) could potentially 
contribute to secondary transmission by contaminating hands of healthcare personnel 
or by contact with medical equipment that will subsequently come in contact with pa-
tients.32 Table 1 and Table 4 list several low-level disinfectants that may be used for 
noncritical items. Table 4 lists the advantages and disadvantages of the low-level dis-
infectants that are used on noncritical patient care items (eg, blood pressure cuffs) and 
noncritical environmental surfaces. The exposure time for low-level disinfection of 
noncritical items is at least 1 minute.Physicians use endoscopes to diagnose and treat numerous medical disorders.
Although endoscopes represent a valuable diagnostic and therapeutic tool in modern
medicine, more health care–associated outbreaks have been linked to contaminated
endoscopes than to any other reusable medical device.6,8 Additionally, endemic
transmission of infections associated with GI endoscopes may go unrecognized for
several reasons, including inadequate surveillance of outpatient procedures, long
lag time between colonization and infection, low frequency of infection, and because
pathogens are the usual enteric flora. In addition, the risk of some procedures might
be lower than others (eg, colonoscopy vs ERCP), whereby normally sterile areas are
contaminated in the latter. In order to prevent the spread of health care–associated
infections (HAIs), all heat-sensitive endoscopes (eg, GI endoscopes, bronchoscopes,
nasopharyngoscopes) must be properly cleaned and, at a minimum, subjected to
HLD following each use. HLD can be expected to destroy all microorganisms;
although when high numbers of bacterial spores are present, a few spores may
survive.
Recommendations for the cleaning and disinfection of endoscopic equipment have
been published and should be strictly followed.13,35,36 Unfortunately, audits have
shown that personnel often do not adhere to guidelines on reprocessing5 and out-
breaks of infection continue to occur.3,6,8,37 Additionally, recent studies have sug-
gested that current reprocessing guidelines are not sufficient to ensure successful
decontamination.38 In order to minimize patient risks and ensure that reprocessing
personnel are properly trained, there should be initial and annual competency testing
for each individual who is involved in reprocessing endoscopic instruments.13,35,36
In general, endoscope disinfection or sterilization with a liquid chemical sterilant or
high-level disinfectant involves 5 steps after leak testing: (1) clean: mechanically clean
internal and external surfaces, including brushing internal channels and flushing each
internal channel with water and a enzymatic cleaner or detergent; (2) disinfect:
immerse endoscope in high-level disinfectant (or chemical sterilant) and perfuse (elim-
inates air pockets and ensures contact of the germicide with the internal channels)
disinfectant into all accessible channels, such as the suction/biopsy channel and
air/water channel, and expose for a time recommended for specific products; (3) rinse:
rinse the endoscope and all channels with sterile water, filtered water (commonly used
CURRENT ISSUES IN DISINFECTION AND STERILIZATION
Reprocessing of Endoscopes
Table 4
Summary of advantages and disadvantages of disinfectants used as low-level disinfectants
Disinfectant
Active Advantages Disadvantages





 Used to disinfect small sur-
faces, such as rubber stoppers
on medication vials
 No toxic residue
 It is not sporicidal.
 It is affected by organic matter.
 It is slow acting against non-
enveloped viruses (eg,
norovirus).
 It has no detergent or cleaning
properties.
 It is not EPA registered.
 It damages some instruments
(eg, harden rubber, deterio-
rate glue).
 It is flammable. (Large
amounts require special
storage.)
 It evaporates rapidly making
contact time compliance
difficult.
 It is not recommended for use
on large surfaces.
 Outbreaks are ascribed to
contaminated alcohol.33




 Inexpensive (in diluted form)
 Not flammable
 Unaffected by water hardness
 Reduces biofilms on surfaces
 Relatively stable (eg, 50%
reduction in chlorine concen-
tration in 30 d)34
 Used as the disinfectant in
water treatment
 EPA registered
 There is a reaction hazard with
acids and ammonias.
 It leaves a salt residue.
 Corrosive to metals (some
ready-to-use products may be
formulated with corrosion
inhibitors)
 It is unstable when active.
(Some ready-to-use products
may be formulated with
stabilizers to achieve longer
shelf-life.)
 It is affected by organic matter.
 It discolors/stains fabrics.
 A potential hazard is produc-
tion of trihalomethane.
 It has an odor. (Some ready-to-
use products may be
formulated with odor
inhibitors.). It is irritating at
high concentrations.
Improved HP  Bactericidal, tuberculocidal,
fungicidal, virucidal
 Fast efficacy
 Easy compliance with wet-
contact times
 Safe for workers (lowest EPA
toxicity category, IV)





 It is more expensive than most
other disinfecting actives.
 It is not sporicidal at low
concentrations.





Iodophors  Bactericidal, mycobactericidal,
virucidal
 Not flammable
 Used for disinfecting blood
culture bottles
 It is not sporicidal.
 It is shown to degrade silicone
catheters.
 It requires prolonged contact
to kill fungi.
 It stains surfaces.
 It is used mainly as an anti-
septic rather than disinfectant.
Phenolics  Bactericidal, tuberculocidal,
fungicidal, virucidal




 It is not sporicidal.
 It is absorbed by porous mate-
rials and irritates tissue.
 Depigmentation of skin is
caused by certain phenolics.
 It can cause hyperbilirubine-

















 Inexpensive (in diluted form)
 It is not sporicidal.
 In general, it is not tuberculo-
cidal and virucidal against
nonenveloped viruses.
 High water hardness and cot-
ton/gauze can make less
microbicidal.
 A few reports documented
asthma as a result of exposure
to benzalkonium chloride.
 It is affected by organic matter.
 Multiple outbreaks ascribed to
contaminated benzalkonium
chloride.33
Peracetic acid/HP  Bactericidal, fungicidal,
virucidal, and sporicidal (eg,
Clostridium difficile)
 Active in the presence of
organic material
 Environmental friendly by-
products (acetic acid, O2, H20)
 EPA registered
 Surface compatible
 It lacks stability.
 It has potential for material
incompatibility (eg, brass,
copper).
 It is more expensive than most
other disinfecting actives.
 The odor may be irritating.
If low-level disinfectant is prepared on-site (not ready to use), document correct concentration at a
routine frequency.
Abbreviations: EPA, Environmental Protection Agency; HIV, human immunodeficiency virus; HP,
hydrogen peroxide.
Adapted from Rutala WA, Weber DJ. Selection of the ideal disinfectant. Infect Control Hosp Epi-
demiol 2014;35:855–65; and Rutala WA, Weber DJ. Disinfection and sterilization in healthcare fa-
cilities. In: Han J, editor. SHEA practical healthcare epidemiology. University of Chicago Press.with automated endoscope reprocessors), or tap water; (4) dry: rinse the insertion tube
and inner channels with alcohol and dry with forced air after disinfection and before
storage; and (5) store: store the endoscope in a way that prevents recontamination
and promotes drying (eg, hung vertically).
Outbreaks of carbapenem-resistant Enterobacteriaceae infection associated with
duodenoscopes: what can we do to prevent infections?
In the past 3 years, multiple reports of outbreaks have led the FDA, the CDC, and na-
tional news to raise awareness among the public and health care professionals that
the complex design of duodenoscopes (used primarily for ERCP) may impede effec-
tive reprocessing. Several recent publications have associated multidrug-resistant
(MDR) bacterial infections, especially due to CRE, in patients who have undergone
ERCP with reprocessed duodenoscopes.3,4,25,37,39 Unlike other endoscope out-
breaks,6 these recent outbreaks occurred even when the manufacturer’s instructions
and professional guidelines were followed correctly.3,4
The key concern raised by these outbreaks is that current reprocessing guidelines
are not adequate to ensure a patient-safe GI endoscope (one devoid of potential path-
ogens), as the margin of safety associated with reprocessing endoscopes is minimal
or nonexistent. There are at least 2 (and maybe 3) reasons for this reprocessing failure
and why outbreaks continue to occur. First, studies have shown that the internal chan-
nel of GI endoscopes, including duodenoscopes, may contain 10710 (7–10-log10)
enteric microorganisms.40,41 Investigations have demonstrated that the cleaning
step in endoscope reprocessing results in a 2- to 6-log10 reduction of microbes and
the HLD step results in another 4- to 6-log10 reduction of mycobacteria for a total 6-
to 12-log10 reduction of microbes.
40–42 Thus, the margin of safety associated with
cleaning and HLD of GI endoscopes is minimal or nonexistent (level of contamination:
4-log10 [maximum contamination, minimal cleaning/HLD] to 5-log10 [minimum
contamination, maximum cleaning/HLD]). Therefore, any deviation from proper
reprocessing (such as crevices associated with the elevator channel) could lead to fail-
ure to eliminate contamination with a possibility of subsequent patient-to-patient
transmission. This low (or nonexistent) margin of safety associated with endoscope
reprocessing compares with the 17-log10 margin of safety associated with cleaning
and sterilization of surgical instruments.23
Second, GI endoscopes not only have heavy microbial contamination (107–1010
bacteria) but they are also complex with long, narrow channels, right-angle turns,
and difficult-to-clean and disinfect components (eg, elevator channel). The elevator
channel in duodenoscopes is unique to side-viewing endoscopes. It has a separate
channel and provides orientation of catheters, guidewires, and accessories into the
endoscopic visual field.25 This channel is complex in design and has crevices that
are difficult to access with a cleaning brush and may impede effective reprocessing.43
Based on this and other recent studies, it is likely that MDR pathogens are acting as
marker or indicator organisms for ineffective reprocessing of the complex design of
duodenoscopes, which is an infectious risk to patients.
Third, biofilms could impact endoscope reprocessing failure and continued
endoscope-related outbreaks.44 Biofilms are multilayered bacteria plus exopolysac-
charides that cement cells to surfaces. They develop in a wet environment. If reproc-
essing is performed promptly after use and the endoscope is dry, the opportunity for
biofilm formation is minimal.45,46 However, the formation of endoscopic biofilm during
clinical practice may be related to reuse of reprocessing methods, such as reuse of
detergent, manual cleaning, and incomplete drying.47 Ideally, reprocessing should
be initiated within an hour of use; however, there are no evidence-based guidelines
on delayed endoscope reprocessing.48 It is unclear if biofilms contribute to failure of
endoscope reprocessing.
What should we do now? Unfortunately, there is currently no single, simple,
and proven technology or prevention strategy that hospitals can use to guarantee
patient safety. Of course, we must continue to emphasize the enforcement of
There is excellent evidence in the scientific literature that environmental contamination
plays an important role in the transmission of several key health care–associated path-
ogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant Enterococcus (VRE), Acinetobacter sp, norovirus, and Clostridium
difficile.50–53 All these pathogens have been demonstrated to persist in the environ-
ment for days (in some cases months), frequently contaminate the environmental sur-
faces in rooms of colonized or infected patients, transiently colonize the hands of
health care personnel, be transmitted by health care personnel, and cause outbreaks
in which environmental transmission was deemed to play a role. Importantly, a study
by Stiefel and colleagues54 demonstrated that contact with the environment was just
as likely to contaminate the hands of health care personnel as was direct contact with
patients. Further, admission to a room in which the previous patient had been colo-
nized or infected with MRSA, VRE, Acinetobacter or C difficile has been shown to
be a risk factor for newly admitted patients to develop colonization or infection.55–57
Improving room cleaning and disinfection and demonstrating the effectiveness of
surface decontamination in reducing health care–associated infections
Investigators have reported that intervention programs aimed at improving surface
cleaning and disinfection reduced HAIs.58 Such interventions have generally included
multiple activities: disinfectant product substitutions and interventions to improve the
effectiveness of cleaning and disinfection (eg, improved housekeeper education,
monitoring the thoroughness of cleaning [eg, by use of ATP assays or fluorescent
dyes] with feedback of performance to the environmental service workers, and/or
use of cleaning checklists).58–61 Health care facilities must also allow adequate time
evidenced-based practices, including equipment maintenance, and routine audits 
with at least yearly competency testing of reprocessing staff.13,35,36 All reprocessing 
personnel must be knowledgeable and thoroughly trained on the reprocessing instruc-
tions for duodenoscopes. This training includes the new recommendations to use a 
small bristle cleaning brush and for additional flushing and cleaning steps of the duo-
denoscope elevator channel (http://medical.olympusamerica.com/sites/default/files/
pdf/150326_TJF-Q180V_Customer_letter.pdf). Although these steps were described 
as validated, no public data are available on the ability of these new cleaning recom-
mendations to yield an ERCP scope devoid of bacteria. But we must do more or addi-
tional outbreaks will likely continue. For example, all hospitals that reprocess 
duodenoscopes should select one of the enhanced methods for reprocessing duode-
noscopes. These enhanced methods have been priority ranked with the first providing 
the greatest margin of safety.25 They include (1) ETO sterilization after HLD with peri-
odic microbiologic surveillance; (2) double HLD with periodic microbiologic surveil-
lance; (3) HLD with scope quarantine until negative culture results are returned; (4) 
liquid chemical sterilant processing system using peracetic acid (rinsed with exten-
sively treated potable water) with periodic microbiologic surveillance; (5) other FDA-
cleared low-temperature sterilization technology (provided material compatibility 
and sterilization validation testing performed using the sterilizer and endoscope) after 
HLD, with periodic microbiologic surveillance; and (6) HLD with periodic microbiologic 
surveillance. These supplemental measures to enhance duodenoscope reprocessing 
made in May-June 201525 were reinforced by the FDA in August 2015.43 UNC Hospi-
tals has chosen ETO sterilization after HLD with periodic microbiologic surveillance as 
its primary reprocessing method for duodenoscopes and if the ETO sterilizer is not 
available, then double HLD with periodic microbiologic surveillance.49
Role of the Environment in Disease Transmission
for room processing to ensure adherence to all steps recommended by institutional
policies and professional organization guidelines. The authors have found that collab-
oration between infection prevention and environmental services staff, nursing, and
management is critical to an effective environmental cleaning program. This collabo-
ration includes ensuring that environmental services staff recognize the significance
and relationship of adhering to proper work procedures to reduction of microbial
contamination. The assignment of cleaning responsibility (eg, medical equipment to
be cleaned by nursing; environmental surfaces to be cleaned by environmental ser-
vice) is also important to ensure all objects and surfaces in a patient room are decon-
taminated, especially the surfaces of medical equipment (eg, cardiac monitors).
Improved environmental cleaning has been demonstrated to reduce the environ-
mental contamination with VRE,61 MRSA,62 and C difficile.63 Further, all studies
have only focused improvement on a limited number of high-risk objects. Thus, a
concern of published studies is that they have only demonstrated improved cleaning
of a limited number of high-risk objects (or targeted objects) not an improvement in the
overall thoroughness of room decontamination, which is the objective.
To the authors’ knowledge only one study has objectively evaluated what consti-
tutes high-touch objects in a patient room and no study has demonstrated epidemio-
logically what constitutes a high-risk object. Examples of what the literature refers to
as high-touch objects includes bed rails, intravenous (IV) poles, call buttons, door
knobs, floors, and bathroom facilities64; however, a study demonstrated high-touch
objects in the intensive care unit were the bed rail, bed surface, and supply cart,
whereas the high-touch surfaces in a patient ward were the bed rail, over-bed table,
IV pump, and bed surface.65 Importantly, the level of microbial contamination of
room surfaces was not statistically different regardless of how often they were
touched before and after cleaning. Until research identifies which objects and surfaces
pose the greatest risk of pathogen transmission, all noncritical surfaces that are
touched must be cleaned/disinfected.66No-touch (or mechanical) methods for room decontamination
As noted earlier, multiple studies have demonstrated that environmental surfaces and
objects in rooms are frequently not properly cleaned and these surfaces may be
important in transmission of health care–associated pathogens. Further, although
interventions aimed at improving cleaning thoroughness have demonstrated effective-
ness, many surfaces remain inadequately cleaned and, therefore, potentially contam-
inated. For this reason, several manufacturers have developed room disinfection units
that can decontaminate environmental surfaces and objects. These no-touch systems
generally use one of 2 methods: either UV light or HPV/mist.53 These technologies
supplement, but do not replace, standard cleaning and disinfection because surfaces
must be physically cleaned of dirt and debris.
Ultraviolet light for room decontamination UV radiation has been used for the control
of pathogenic microorganisms in a variety of applications, such as control of legion-
ellosis, as well as disinfection of air, surfaces, and instruments.53,67 At certain wave-
lengths, UV light will break the molecular bonds in DNA, thereby destroying the
organism. UV radiation has peak germicidal effectiveness in the wavelength range
of 240 to 280 nm. Mercury gas bulbs emit UV-C at 254 nm, whereas xenon gas bulbs
produce a broad spectrum of radiation that encompasses the UV (100–280 nm) and
the visible (380–700 nm) electromagnetic spectra.68 The efficacy of UV radiation is a
function of many different parameters such as dose, distance, direct or shaded expo-
sure, exposure time, lamp placement, pathogen, carrier or surface tested, inoculum
 
Disinfection and sterilization are critical components of infection control. Unfortu-
nately, breaches of disinfection and sterilization guidelines are not uncommon. Patient
notifications due to improper reprocessing of semicritical (eg, endoscopes) and critical
medical instruments have occurred regularly.7 This referenced article also provides a
method for assessing patient risk for adverse events, especially infection. Use of a
14-step algorithm (Box 2) can guide an institution in managing potential disinfection
and sterilization failures.7,86
Human Papilloma Virus
Human papilloma virus is an extremely common sexually acquired infection and is the
most important cause of cervical cancer. A 2014 article reported that the FDA-cleared
high-level disinfectants (ie, glutaraldehyde, OPA) tested did not inactivate human pap-
illoma virus, a nonenveloped virus.87 These findings are inconsistent with many
method, organic load and orientation of carriers (eg, parallel vs perpendicular). Data 
demonstrate that several UV systems have effectiveness (eg, eliminate >3-log10 vege-
tative bacteria [MRSA, VRE, Acinetobacter baumannii] and >2.4-log10 C difficile) at
relatively short exposure times (eg, 5–25 minutes for bacteria, 10–60 minutes for C 
difficile spores).68–70 The studies also demonstrated reduced effectiveness when sur-
faces were not in direct line-of-sight.68–72
Hydrogen peroxide systems for room decontamination Several systems that produce 
HP (eg, HPV, aerosolized dry mist HP) have been studied for their ability to decontam-
inate environmental surfaces and objects in hospital rooms. HPV has been used for 
the decontamination of rooms in health care.73–83 Studies have demonstrated that 
HP systems are a highly effective method for eradicating various pathogens (eg, 
MRSA, Mycobacterium tuberculosis, Serratia, C difficile spores, Clostridium botulinum 
spores) from rooms, furniture, and equipment.
Comparison of ultraviolet irradiation versus hydrogen peroxide for room 
decontamination UV devices and HP systems have their own advantages and disad-
vantages (Table 5),53 and there is now ample evidence that these no-touch systems 
can reduce environmental contamination with health care–associated pathogens 
and reduce HAIs.84 However, each specific marketed system should be studied and 
its efficacy demonstrated before being introduced into health care facilities. The 
main advantage of both types of units is their ability to achieve substantial reductions 
in vegetative bacteria. Another advantage is their ability to substantially reduce C diffi-
cile spores, as low-level disinfectants (such as quaternary ammonium compounds) 
have only limited or no measurable activity against spore-forming bacteria.85 Both 
systems are residual free, and they decontaminate all exposed surfaces and equip-
ment in the room.
Based on data that demonstrated a reduction of colonizations and/or infections 
associated with these technologies, the authors recommend they should be used 
for terminal room decontamination after discharge of patients on contact precautions. 
Because different UV and HP systems vary substantially, infection preventionists 
should review the peer-reviewed literature and the advantages/disadvantages of 
each technology (Box 1) and choose only devices with demonstrated bactericidal 
capability as assessed by carrier tests and/or the ability to disinfect actual patient 
rooms. Ultimately, one would select a device that also has demonstrated the ability 
to reduce HAIs.84
Assessing Risk to Patients from Disinfection and Sterilization Failures
Table 5
Clinical trials using ultraviolet or hydrogen peroxide devices for terminal room disinfection to reduce health care–associated infections













HPV (Bioquell) CDI 2.28–1.28 per 1000
Pt-days (P 5 .047)
No No NA
Cooper, 2011 Before-after (2
cycles)
Hospitals HPV (NS) CDI Decreased cases
(incidence NS)
No No Yes
Levin, 2013 Before-after Community
hospital
UV-PX, Xenex CDI 9.46–4.45 per 10,000


















2.3–1.2 (P 5 .30)
7.2–2.4 (P<.01)
2.4–1.0 (P5.19)
12.6–6.2 per 1000 Pt-
days (P<.01)
No No No
Manian, 2013 Before-after Community
hospital
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Miller, 2015 Before-after Urban
hospital
UV-PX, Xenex CDI 23.3–8.3 per 10,000
Pt-days (P 5 .02)
No No Yes
Nagaraja, 2015 Before-after Academic
center
UV-PX, Xenex CDI 1.06–0.83 per 1000
Pt-days (P 5 .06)
No No No
Pegues, 2015 Before-after Academic
center
UV-C (Optimum) CDI 30.34–22.85 per
10,000 Pt-days




Anderson, 2015 RCT 9 Hospitals UV-C (Tru-D) MRSA, VRE, CDI 51.3–33.9 per 10,000
Pt-days (P 5 .036)
Yes Yes No
Abbreviations: CDI, Clostridium difficile infections; CI, confidence interval; EVS, environmental service; GNB, gram-negative bacteria; HH, hand hygiene; IRR, inci-
dence rate ratio; MDRO, multidrug-resistant organism; NA, not applicable; NS, not stated; Pt, patient; RCT, randomized controlled trial; UV-PX, ultraviolet light,
pulsed xenon device.
Adapted from Weber DJ, Rutala WA, Anderson DJ, et al. Effectiveness of UV devices and hydrogen peroxide systems for terminal room decontamination: focus
on clinical trials. Am J Infect Control 2016;44(5 Suppl):e77–84.
Box 1




 There is reliable biocidal activity against a wide range of health care–associated pathogens.
 Room surfaces and equipment are decontaminated.
 There is rapid room decontamination (w5–25 minutes) for vegetative bacteria, which
reduces the downtime of the room before another patient can be admitted.
 It is demonstrated to reduce HAIs (eg, C difficile, MRSA).
 It is effective against C difficile, although requires longer exposure (w10–50 minutes).
 HVAC system does not need to be disabled and the room does not need to be sealed.
 UV is residual free and does not give rise to health or safety concerns.
 There are no consumable products, so costs include only capital equipment and staff time.
 There is good distribution in the room of UV energy via an automated monitoring system.
Disadvantages
 All patients and staff must be removed from the room before decontamination, thus,
limiting use to terminal room decontamination.
 Decontamination can only be accomplished at terminal disinfection (ie, cannot be used for
daily disinfection) as room must be emptied of people.
 Capital equipment costs are substantial.
 It does not remove dust and stains, which are important to patients and visitors; hence,
cleaning must precede UV decontamination.
 It is sensitive to use parameters (eg, dose, distance, carrier or surface tested, exposure time,
pathogen).
 It requires that equipment and furniture be moved away from the walls.
HP systems
Advantages
 It has reliable biocidal activity against a wide range of health care–associated pathogens.
 Room surfaces and equipment are decontaminated.
 It has been demonstrated to reduce HAIs (eg, C difficile, MRSA, VRE).
 It is useful for disinfecting complex equipment and furniture.
 It does not require that furniture and equipment be moved away from the walls.
 HP is residual free and does not give rise to health or safety concerns (aeration unit converts
HP into oxygen and water).
 There is uniform distribution in the room via an automated dispersal system.
Disadvantages
 All patients and staff must be removed from the room before decontamination, thus,
limiting use to terminal room decontamination.
 HVAC systemmust be disabled to prevent unwanted dilution of HP during use, and the doors
must be closed with gaps sealed by tape.
 Decontamination can only be accomplished as terminal disinfection (ie, cannot be used for
daily disinfection) as room must be emptied of people.
 Capital equipment costs are substantial.
 Decontamination requires approximately 2.0 to 5.0 hours.
 It does not remove dust and stains, which are important to patients and visitors; hence,
cleaning must precede UV decontamination.
 It is sensitive to use parameters (eg, HP concentration, pathogen, exposure time).
Abbreviation: HVAC, heating, ventilation, and air conditioning.
Adapted from Rutala WA, Weber DJ. Disinfectants used for environmental disinfection and
new room decontamination technology. Am J Infect Control 2013;41:S36–41.
Box 2
Protocol for exposure investigation after the failure to follow disinfection and sterilization
principles
1. Confirm disinfection or sterilization reprocessing failure
2. Embargo any improperly disinfected or sterilized items
3. Do not use the questionable disinfection or sterilization unit (eg, sterilizer, automated
endoscope reprocessor)
4. Inform key stakeholders
5. Conduct a complete and thorough evaluation of the cause of the disinfection/sterilization
failure
6. Prepare a line listing of potentially exposed patients
7. Assess whether disinfection or sterilization failure increases patient risk for infection
8. Inform expanded list of stakeholders of the reprocessing issue
9. Develop a hypothesis for the disinfection or sterilization failure and initiate corrective
action
10. Develop a method to assess potential adverse patient events
11. Consider notification of state and federal authorities
12. Consider patient notification
13. Develop long-term follow-up plan
14. Perform after-action report
Adapted from Rutala WA, Weber DJ. How to assess risk of disease transmission to patients
when there is a failure to follow recommended disinfection and sterilization guidelines. Infect
Control Hosp Epidemiol 2007;28:146–55.articles in the peer-reviewed literature, which demonstrates that high-level disinfec-
tants, such as OPA and glutaraldehyde, inactivate nonenveloped viruses, such as
hepatitis A virus, polio, adenovirus, norovirus, and so forth. Because the high-level dis-
infectants are commonly used to disinfect endocavitary probes (eg, vaginal probes,
rectal probes), there is an urgency to corroborating these data. In a conversation
with CDC staff regarding this issue, it was determined hospitals should continue to
use the FDA-cleared high-level disinfectants consistent with the manufacturers’ in-
structions until the data can be corroborated. Data have demonstrated the activity
of a HP mist device to inactivate human papilloma virus.88
Hydrogen Peroxide Mist System for Probes
Although the most common way of performing HLD of contaminated endocavitary
probes is by immersion in an FDA-cleared high-level disinfectant (eg, glutaraldehyde),
an alternative procedure for disinfecting the endocavitary and surface probes is a HP
mist system, which uses 35% HP at 56C with the probe reaching no more than
40C (ie, Trophon EPR, Nanosonics, Alexandria, Australia). In one study, the results
demonstrated complete inactivation (>6-log10 reduction) of VRE and a CRE-Klebsiella
pneumoniae strain both in the presence and absence of 5% fetal calf serum (FCS). The
Trophon EPR system showed good, but not complete, inactivation of Mycobacterium
terrae (5.2-log10 reduction for M terrae with FCS, a 4.6-log10 reduction for M terrae
without FCS) and C difficile spores (5.1-log10 reduction for C difficile spores
with FCS, 6.2-log10 reduction for C difficile spores without FCS).
89 To simulate a
worse-case condition, cleaningwas not done before disinfection in these experiments;
but proper cleaning of probes is necessary to ensure the success of high-level disinfec-
tion. Other data have demonstrated the activity of Trophon to inactivate human papil-
loma virus88 and other pathogens (eg, bacteria, mycobacteria, viruses) including a
greater than 6-log10 reduction of M terrae and C difficile spores in carrier tests and a
greater than 6-log10 reduction inM terrae on inoculated ultrasound probes.
90 These re-
sults differ slightly from those presented earlier, presumably because of the differences
in testing methodology. In the authors’ study only the probe devices were inoculated
(carriers of different materials were not tested); for recovery of bacteria on the probe,
the probes were immersed in media (not swabbed, which would likely result in lower
recovery).89 The Trophon system processes the portion of the probe that has mucous
membrane contact but also the handle of endocavitary probes, whichmay be contam-
inated; it is an alternative to high-level chemical disinfection for ultrasound probes.
Do Not Reuse Single-Use Devices
The Department of Justice and the FDA have joined forces in prosecuting health care
providers that reuse single-use devices. For example, one physician was criminally
prosecuted for reusing needle guides meant for single use during prostate proce-
dures. These prosecutions are based on conspiracy to commit adulteration and Medi-
care fraud. Third-party reprocessing is allowed by the FDA as the reprocessor is
considered the devicemanufacturer as defined under the Code of Federal Regulations
Title 21 Part 820.
Storage of Semicritical Items
In 2011, The Joint Commission (TJC) recommended that laryngoscope blades be
packaged in a way that prevents recontamination. Examples of compliant storage
include, but are not limited to, a peel pouch or a closed plastic bag. Examples of non-
compliant storage would include unwrapped blades in an anesthesia drawer as well as
an unwrapped blade on top of or within a code cart. The packaging not only prevents
recontamination but also distinguishes a processed from a nonprocessed semicritical
item, such as a specula, laryngoscope blade, or endoscope. The use of a tagging sys-
tem, in both inpatient and outpatient facilities,91 that separates processed from non-
processed itemsminimizes the risk that a nondisinfected, semicritical device would be
used and potentially lead to cross-transmission of a pathogen.7 This tagging system
could involve a tag (eg, green tag, patient ready; red tag, requires reprocessing) for
GI endoscopes or a plastic sheath or plastic-paper peel pouch (eg, endocavitary
probes). Ideally, hospitals and ambulatory care facilities91 (as appropriate) should
develop a strategy (eg, tagging, storage covers for patient-ready devices) that pre-
vents patient exposures to contaminated devices.
Immersion Versus Perfusion of Channel Scopes Such as Cystoscopes
In the United States, it is estimated that more than 4 million cystoscopies are per-
formed each year.29,92 Cystoscopy is a diagnostic procedure that uses an endoscope
especially designed to examine the bladder, lower urinary tract, and prostate gland or
is used to collect urine samples, perform biopsies, and remove small stones. A flexible
or rigid scope can be used to carry out the procedure. Because the procedure, and
other channeled scopes (eg, hysteroscopes, some nasopharyngoscopes), involves
a medical device in contact with the patients’ mucous membranes, it is considered
a semicritical device that must minimally be high-level disinfected.
The authors recently evaluated the disinfection of cystoscopes, and their results
demonstrated that disinfection (ie, a reduction in bacterial load of greater than
Laryngoscopes are routinely used to view the vocal cords and larynx and facilitate
airway management. It typically consists of a blade that connects to a handle, which
usually contains 2 batteries that power the light source. Limited guidelines are avail-
able for reprocessing laryngoscope blades and handles, and hospital practices
vary.95–97 For example, some guidelines recommend and hospitals use low-level
disinfection of the handle as it does not have direct contact with a mucous membrane,
whereas others recommend the handle be high-level disinfected to prevent disease
transmission. Although blades have been linked to HAIs, handles have not been
directly linked to HAIs. However, reports of contamination with blood (40% of the han-
dles positive for occult blood) and potentially pathogenic microorganisms (86% of the
handles deemed ready for patient use were contaminated with pathogens, such as S
aureus, Acinetobacter) suggest its potential,97–100 and the blade and handle function
together. For this reason, it is ideal that the blades and handles be high-level disin-
fected or sterilized even if a protective barrier or sheath is used during the procedure.
In 2007, the state of California required that both blades and handles be HLD or ster-
ilized. UNC Hospitals is sterilizing the blades and handles (ie, blades via HP gas
plasma, handle [without batteries] by steam). Other methods for HLD or sterilization
are acceptable, but one must ensure the blade and handle are compatible with the
HLD or sterilization process chosen. After sterilization the blades and handles are
checked for function before packaging and then packaged in a Ziploc bag. Per
TJC, the laryngoscope blade and handle must be packaged in a way that prevents
recontamination after processing (Frequently Asked Questions, The Joint Commis-
sion, October 24, 2011). Examples of compliant storage include, but are not limited
to, a peel pack after sterilization (long-term storage) or wrapping in a sterile towel
(short-term storage).
Recent advances in video technology have led to the development of video laryn-
goscopes, such as the GlideScope (Verathon Medical, Bothell, WA) and McGrath
(Medtronic, Minneapolis, MN) video laryngoscopes.92 These new intubation devices
assist in difficult airway management. For the McGrath an image is displayed on a
liquid-crystal display screen that is contained within a monitor mounted to the
handle of the device. A sterile, single-use disposable laryngoscope blade covers
the camera and light-emitting diode assembly to prevent direct patient contact.
Even though a cover is used, HLD or sterilization via ETO or HP gas plasma (battery
removed) is recommended for the McGrath MAC video laryngoscope.93 The manu-
facturer states, whenever practical, a HLD or sterilization is preferred to a wipe-
based process.
7-log10 colony-forming unit [CFU]) did not occur unless the channel was actively 
perfused with the glutaraldehyde. In fact, failure to perfuse the channel led to only min-
imal, if any, reduction in bacterial contamination. However, complete inactivation of 
108 CFU of both VRE and CRE was achieved when the channel was actively perfused. 
It seems that no high-level disinfectant entered the channel unless it was actively 
perfused, as the level of microbial contamination was not reduced by immersion.29 
This failure to perfuse the channel occurs because the air pressure in the channel is 
stronger than the fluid pressure at the fluid-air interface. Recommendations are pro-
vided for cystoscope HLD and include actively perfusing the device while immersed 
in the high-level disinfectant.93 Unfortunately, some cystoscope reprocessing recom-
mendations published in the literature are incorrect. For example, investigators have 
recommended complete immersion of the cystoscope into the high-level disinfectant 
but did not mention perfusion of the high-level disinfectant into the channel.94
Laryngoscopes
The portable GlideScope video laryngoscope system is available in a single-use
and a reusable configuration. They should be cleaned and disinfected per the manu-
facturer’s recommendations. The single-use system features a reusable video baton
and sterile stats that must be disposed of immediately after use. Low-level disinfection
is recommended for the video baton after each use using an Environmental Protection
Agency–registered disinfectant (eg, antimicrobial disposable wipe per manufacturer’s
instructions) after each use. The manufacturer recommends HLD for the video baton
when it is visibly soiled.
The manufacturer recommends that the advanced video laryngoscope reusable
blade be high-level disinfected and the GlideRite rigid stylets be sterilized.101
Emerging Pathogens, Antibiotic-Resistant Bacteria, and Bioterrorism Agents
Emerging pathogens are of growing concern to the general public and infection
control professionals. Relevant pathogens include Ebola,102 MDR organisms such
as CRE, Enterovirus D68, MDR pathogens, Middle East respiratory syndrome-
Coronavirus, MDRM tuberculosis, human papilloma virus, norovirus, and nontubercu-
lous mycobacteria (eg, M chelonae). The susceptibility of each of these pathogens to
chemical disinfectants/sterilants has been studied; all of these pathogens (or surro-
gate microbes such as feline-calicivirus for Norwalk virus, vaccinia for variola,103
and Bacillus atrophaeus [formerly B subtilis] for B anthracis) are susceptible to
currently available chemical disinfectants/sterilants.19,104 Standard sterilization and
disinfection procedures for patient-care equipment (as recommended in this article)
are adequate to sterilize or disinfect instruments or devices contaminated with blood
or other body fluids from persons infected with blood-borne pathogens, emerging
pathogens, and bioterrorism agents, with the exception of prions, HPV, and C difficile
spores (see earlier discussion). No changes in current procedures for cleaning, disin-
fecting, or sterilizing need to be made.13
In addition, there are no data to show that antibiotic-resistant bacteria (MRSA, VRE,
MDR M tuberculosis) are less sensitive to the liquid chemical germicides than
antibiotic-sensitive bacteria at currently used germicide contact conditions and
concentrations.105–107
SUMMARY
When properly used, disinfection and sterilization can ensure the safe use of invasive
and noninvasive medical devices. The method of disinfection and sterilization de-
pends on the intended use of the medical device: critical items (contact sterile tissue)
must be sterilized before use; semicritical items (contact mucous membranes or non-
intact skin) must be high-level disinfected; and noncritical items (contact intact skin)
should receive low-level disinfection. Cleaning should always precede HLD and ster-
ilization. Current disinfection and sterilization guidelines must be strictly followed.
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